Literature DB >> 31045236

Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome.

Yuki Shono1, Hiraku Suga, Hiroaki Kamijo, Hikari Fujii, Tomonori Oka, Tomomitsu Miyagaki, Naomi Shishido-Takahashi, Makoto Sugaya, Shinichi Sato.   

Abstract

Tumor cells in cutaneous T-cell lymphoma express limited numbers of chemokine receptors. We investigated the expression patterns of CXCR3, CCR3, CCR4 and CCR10 in mycosis fungoides, Sézary syndrome, lym-phomatoid papulosis and anaplastic large cell lymphoma in 121 skin biopsy samples. CXCR3 was expressed in 86% of mycosis fungoides cases but in no anaplastic large cell lymphoma cases. CCR3 was expressed in 73% of cases of CD30+ lymphoproliferative disorders such as lymphomatoid papulosis and anaplastic large cell lymphoma. Mycosis fungoides/Sézary syndrome patients with high CCR3 or CCR4 expression had a poorer survival prognosis than mycosis fungoides/Sézary syndrome patients whose tumor cells did not express these receptors. CCR10 was expressed in 50% of mycosis fungoides/Sézary syndrome cases and in 13% of cases with CD30+ lym-phoproliferative disorders. These results suggest that differential patterns of CXCR3, CCR3, CCR4 and CCR10 expression are useful for the diagnosis of cutaneous T-cell lymphoma. Moreover, expression of CCR3 or CCR4 suggests a poor prognosis in mycosis fungoides/Sézary syndrome.

Entities:  

Keywords:  CCR10; CCR3; CCR4; CXCR3; CTCL

Year:  2019        PMID: 31045236     DOI: 10.2340/00015555-3207

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  6 in total

1.  Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma.

Authors:  Alyxzandria M Gaydosik; Dawn S Queen; Megan H Trager; Oleg E Akilov; Larisa J Geskin; Patrizia Fuschiotti
Journal:  Blood       Date:  2020-10-08       Impact factor: 22.113

2.  Comprehensive Analysis of Ferroptosis- and Immune-Related Signatures to Improve the Prognosis and Diagnosis of Kidney Renal Clear Cell Carcinoma.

Authors:  Xiao-Liang Xing; Yan Liu; Jiheng Liu; Huanfa Zhou; Huirong Zhang; Qi Zuo; Ping Bu; Tong Duan; Yan Zhou; Zhiquan Xiao
Journal:  Front Immunol       Date:  2022-05-10       Impact factor: 8.786

Review 3.  What does elevated TARC/CCL17 expression tell us about eosinophilic disorders?

Authors:  Julien Catherine; Florence Roufosse
Journal:  Semin Immunopathol       Date:  2021-05-19       Impact factor: 9.623

4.  Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma.

Authors:  Kayo Tanita; Taku Fujimura; Yota Sato; Chunbing Lyu; Yumi Kambayashi; Dai Ogata; Satoshi Fukushima; Azusa Miyashita; Hideki Nakajima; Motoki Nakamura; Akimichi Morita; Setsuya Aiba
Journal:  Front Oncol       Date:  2019-09-20       Impact factor: 6.244

Review 5.  Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?

Authors:  Nathan Karin
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639

6.  Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial.

Authors:  R A Cowan; J J Scarisbrick; P L Zinzani; J P Nicolay; L Sokol; L Pinter-Brown; P Quaglino; L Iversen; R Dummer; A Musiek; F Foss; T Ito; J-P Rosen; M C Medley
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-08-20       Impact factor: 9.228

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.